I'm back in 1990

Chapter 784: Joy or Sorrow?

A month later, the clinical trial application for the novel hematologic malignancy targeted drug, codenamed KRB01, was successively approved by drug regulatory authorities in many countries around the world, including China and Hong Kong.

Following this, this new targeted drug began Phase I clinical trials at multiple clinical centers around the world.

Kangci Hospital and Ruijin Hospital were the first two hospitals to begin Phase I clinical trials. The first batch of volunteers consisted of sixty patients with refractory or relapsed acute lymphoblastic leukemia. They all had one thing in common: they had developed drug resistance to the drugs they were previously using. In other words, the original drugs were no longer effective for them, and they could only wait helplessly for the end of their lives. This trial brought them hope for life.

Thousands of patients signed up, but only sixty were ultimately selected for the first batch of trials. There was no other way; with the clinical trial results still unclear, sixty was the limit.

Xie Xinyue traveled back and forth between Shanghai and Hong Kong constantly, anxiously monitoring every data point. To minimize Xie Xinyue's fatigue during her journey and for her safety, Huang Xiaochuan allocated a newly purchased Bombardier XRS to Xie Xinyue, along with a team of bodyguards who accompanied and protected her 24 hours a day.

In addition to Shanghai and Hong Kong, Xie Xinyue also needs to travel to Southeast Asia, the Middle East, the United States, Europe and other regions and countries to observe and understand the progress of the experiment. Therefore, this newly purchased aircraft has become Xie Xinyue's private jet. However, a total of three aircraft were ordered in the same batch. In addition to this new XRS, there are two Gulfstream 550s. Together with the original old Global Express, the four aircraft form a small fleet to provide travel services for Huang Xiaochuan and his family.

Just before Huang Xiaochuan's two children were about to start fourth grade, Yu Xiang returned from Hong Kong and told him some good news.

"Xiao Chuan, I have good news for you. After taking the medication, more than 98 patients showed a significant decrease in tumor markers within two weeks, and there were no serious adverse reactions. The other two patients died due to their own complications. If they had participated in the experiment earlier, perhaps..." Yu Xiang's expression turned somewhat somber as she said this.

Huang Xiaochuan put his arm around her shoulder and comforted her: "It is indeed great news. Don't be like this. As it stands, this drug can save the lives of most patients, which is already very good. You are a doctor yourself, so you should understand the reasons behind it better than I do."

This news has caused quite a stir. Although Clarif Pharmaceuticals has not yet made any public announcement, the global pharmaceutical giants have all learned of it. These international pharmaceutical companies all have their own intelligence departments, which are dedicated to investigating the current state of pharmaceutical development in the world.

Some international pharmaceutical companies have even started contacting Kerui Pharmaceuticals through intermediaries to explore the possibility of cooperation or acquisition.

Unfortunately, Kerui Pharmaceuticals is not a listed company and has no chance of being acquired. Its shareholders are a complex group, mostly offshore companies or trust funds registered in Bermuda. The only connection is that Kerui Pharmaceuticals is a subsidiary of Hong Kong's Dadao Group, which owns a portion of the pharmaceutical company's shares.

Hong Kong Avenue is a commercial behemoth with diversified industries spanning Southeast Asia, North America, South America, and Europe. It has excellent business performance and a huge cash flow, so it is naturally impossible for it to sell its stake in Kerui Pharmaceuticals.

However, because the potential profits were so enormous, some persistent international pharmaceutical giants still managed to contact Charlie Cho.

But Cao Charlie was just a maid who held the key; she had no say in the household and could not make any decisions. She could only come to Shanghai to report this matter to her boss.

Upon seeing Huang Xiaochuan, Cao Charlie immediately greeted him respectfully: "Mr. Huang!"

"Sit down!" Huang Xiaochuan raised his hand and pressed it down slightly.

"Thank you, Mr. Huang!" Charlie Cao thanked his boss respectfully before sitting down.

After sitting down,

Charlie Cao proactively explained the reason for his trip to Shanghai: "Mr. Huang, three internationally renowned pharmaceutical companies contacted me through intermediaries, wanting to purchase shares in Kerui Pharmaceuticals or buy out the overseas rights of KRB01. In addition, several sovereign wealth funds and trust investment institutions have also contacted us, expressing their desire to invest in Kerui Pharmaceuticals."

Huang Xiaochuan wasn't surprised at all; otherwise, he wouldn't have increased Xie Xinyue's security level and provided her with a private jet to facilitate her safe travels.

This is a groundbreaking drug with astonishing effects. According to preliminary clinical trial data, it has a 98% efficacy rate and no serious adverse reactions. In the pharmaceutical industry, this can be called a "game-changer" drug, enough to change the current rules of the game. It is no exaggeration to say that this drug, which is still in the clinical trial stage, has already caused an earthquake in the field of hematologic malignancy treatment.

It's important to understand that once such a drug is successfully launched, the targeted drugs developed and produced by the world's major pharmaceutical giants for the same indication will be replaced by this new drug, and their market share will be squeezed. The interests and scope involved are simply too great. The other party will certainly not let it develop like this and will try every means to either join in and get a share of the pie or try to destroy this drug.

In other words, this drug is related to a market that could be worth tens or even hundreds of billions of dollars in the future—such a huge pie! Who wouldn't want a piece of it?

Two days before Charlie Cao arrived in Shanghai, Zhang Sui made a encrypted call from New York, specifically reminding Huang Xiaochuan of this matter.

Zhang Sui said on the phone: "Boss! As far as I know, once this project is successfully approved for market launch, it will not only be an earthquake in the pharmaceutical industry, but also a tsunami in the capital market. Now, all the major conglomerates are watching this project."

Therefore, Huang Xiaochuan had already prepared a response. He said to Cao Charlie, "Charlie, give a unified reply to all the pharmaceutical giants, sovereign wealth funds, and trust investment institutions that come to us seeking cooperation."

The company stated that it appreciates the attention from all sectors, and at this stage, it is primarily focused on advancing the clinical trials of krb01 and is not considering any form of equity cooperation or rights transfer. The tone and stance should be firm.

"Understood, Mr. Huang!" Charlie Cao wrote down everything Huang Xiaochuan said.

Afterwards, Cao Charlie reported on other matters of the group. In general, the group and its various subsidiaries were operating in an orderly manner. Huang Xiaochuan focused on the big picture and delegated the small details; he didn't have the energy to delve into the details of management.

After Cao Charlie finished reporting his work, Huang Xiaochuan checked the time and said, "Charlie, I won't keep you any longer."

Charlie Cao was sensible; knowing that the big boss must be busy, he quickly stood up and said, "The group is very busy, and I need to get back as soon as possible."

Huang Xiaochuan waved his hand: "Alright, then I won't keep you any longer. Have a safe journey."

Then Gao Song escorted Cao Charlie downstairs.

The new semester starts tomorrow, and Huang Xiaochuan had already told his two children that he would personally take them to school, so even the biggest things had to give way to this.

I naturally want to go home early in the evening to have dinner with my son and daughter.

After dinner, the couple returned to their room, and Yu Xiang told Huang Xiaochuan something else.

"Hey, you know what? I got some news that new data shows KRB01 also shows promise for treating some other types of hematologic malignancies."

As soon as Yu Xiang said this, Huang Xiaochuan knew that the valuation of this drug was about to double again. He really didn't expect that the "recognition" generated by spending more than 3 billion yuan would be so huge.

With the assets of Kerui Pharmaceuticals and Xie Xinyue about to skyrocket, Huang Xiaochuan didn't know whether to be worried or happy. Of course, Huang Xiaochuan wasn't worried about the growth of Xie Xinyue's personal assets; what worried him was that as this pie grew bigger, more and more people would covet it. Just wait and see, things are about to get interesting.